Literature DB >> 20809396

Comparison of cancer care for hepatocellular carcinoma at two tertiary-care referral centers from high and low endemic regions for viral hepatitis.

Fahad Alsohaibani1, Geoffrey Porter, Hamad Al-Ashgar, Mark Walsh, Robert Berry, Michele Molinari, Kevork Minas Peltekian.   

Abstract

BACKGROUND: Risk factors for hepatocellular carcinoma (HCC) have geographic variability but differences in care have not been described. We reviewed the presentation, management, and outcomes of HCC patients from two tertiary-referral centers in Central Saudi Arabia and Atlantic Canada during 1997-2002.
METHODS: Data were extracted from health records of 96 Saudi and 80 Canadian consecutive patients with HCC.
RESULTS: Mean age (± SEM) of the two groups were similar (64 + 1 and 65 + 1 years) with 93% versus 75% males amongst Canadian and Saudi patients, respectively. In Canada, underlying disease was alcohol-related cirrhosis (45%), cryptogenic cirrhosis (26%), or hepatitis C (13%). For Saudis, HCC cases were attributed to hepatitis C (47%), cryptogenic cirrhosis (27%), and hepatitis B (21%). At initial presentation, Saudi patients had more vascular invasion and distant metastases while Canadians had more advanced liver disease. The tumor-specific prognostic classifications were comparable. Due to center-specific expertise or preference, symptomatic treatment was more common amongst Saudi patients (83% versus 42%) while more Canadians underwent local palliative interventions (52% versus 12%). Frequency of potentially curative therapies including resection and transplantation were similar at both centers. There was no difference in overall median survival (14 versus 10 months) amongst Canadian and Saudi patients.
CONCLUSIONS: This study validates divergence in HCC presentation between low and high endemic regions for viral hepatitis. In addition, for the first time, differences in cancer care of HCC are documented.

Entities:  

Mesh:

Year:  2011        PMID: 20809396     DOI: 10.1007/s12029-010-9200-x

Source DB:  PubMed          Journal:  J Gastrointest Cancer


  22 in total

1.  Estimating the world cancer burden: Globocan 2000.

Authors:  D M Parkin; F Bray; J Ferlay; P Pisani
Journal:  Int J Cancer       Date:  2001-10-15       Impact factor: 7.396

2.  Radiofrequency ablation in the treatment of small hepatocellular carcinoma: a meta analysis.

Authors:  Jun-Guo Liu; Yi-Jun Wang; Zhi Du
Journal:  World J Gastroenterol       Date:  2010-07-21       Impact factor: 5.742

Review 3.  Positioning and indication of sorafenib in the treatment algorithm and real practice setting: Western and eastern approach--Asian perspective.

Authors:  Jung Min Lee; Kwang-Hyub Han
Journal:  Oncology       Date:  2010-07-08       Impact factor: 2.935

4.  Occurrence of cirrhosis-related complications is a time-dependent prognostic predictor independent of baseline model for end-stage liver disease score.

Authors:  Teh-Ia Huo; Han-Chieh Lin; Fa-Yauh Lee; Ming-Chih Hou; Pui-Ching Lee; Jaw-Ching Wu; Full-Young Chang; Shou-Dong Lee
Journal:  Liver Int       Date:  2006-02       Impact factor: 5.828

5.  Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States.

Authors:  H B El-Serag; A C Mason; C Key
Journal:  Hepatology       Date:  2001-01       Impact factor: 17.425

6.  Prognosis of hepatocellular carcinoma: the BCLC staging classification.

Authors:  J M Llovet; C Brú; J Bruix
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

Review 7.  Use of tamoxifen in advanced-stage hepatocellular carcinoma. A systematic review.

Authors:  Anna K Nowak; Martin R Stockler; Pierce K H Chow; Michael Findlay
Journal:  Cancer       Date:  2005-04-01       Impact factor: 6.860

8.  Risk factors in development of hepatocellular carcinoma in cirrhosis: prospective study of 613 patients.

Authors:  S N Zaman; W M Melia; R D Johnson; B C Portmann; P J Johnson; R Williams
Journal:  Lancet       Date:  1985-06-15       Impact factor: 79.321

9.  Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial. CLIP Group (Cancer of the Liver Italian Programme)

Authors: 
Journal:  Lancet       Date:  1998-07-04       Impact factor: 79.321

Review 10.  Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials.

Authors:  R G Simonetti; A Liberati; C Angiolini; L Pagliaro
Journal:  Ann Oncol       Date:  1997-02       Impact factor: 32.976

View more
  2 in total

1.  Saudi Association for the Study of Liver diseases and Transplantation practice guidelines on the diagnosis and management of hepatocellular carcinoma.

Authors:  Saleh A Alqahtani; Faisal M Sanai; Ashwaq Alolayan; Faisal Abaalkhail; Hamad Alsuhaibani; Mazen Hassanain; Waleed Alhazzani; Abdullah Alsuhaibani; Abdullah Algarni; Alejandro Forner; Richard S Finn; Waleed K Al-Hamoudi
Journal:  Saudi J Gastroenterol       Date:  2020-10       Impact factor: 2.485

Review 2.  Relative Importance of Hepatitis B and C Viruses in Hepatocellular Carcinoma in EMRO Countries and the Middle East: A Systematic Review.

Authors:  Seyed Moayed Alavian; Hossein Haghbin
Journal:  Hepat Mon       Date:  2016-03-06       Impact factor: 0.660

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.